Imidazole Fused Polycyclic Compounds for Multidrug-Resistant Bacteria
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The rapid emergence of antibiotic-resistant bacteria, particularly multidrug-resistant strains of Staphylococcus aureus, poses a significant clinical and public health challenge due to limited therapeutic options, with existing antimicrobials leading to quick resistance development and high mortality rates.
Innovation Solution
Development of novel imidazole fused polycyclic systems through privileged substructure-based diversity-oriented synthesis, which are synthesized via Groebke and aza-Michael reactions, exhibiting potent antibacterial activity against Gram-positive bacteria including multidrug-resistant Staphylococcus species.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemical variants of older antibiotics are developed, then antibacterial activity is maintained, but resistance develops quickly
Solution Approach 1:
The patent applies segmentation by dividing the antibiotic development approach into distinct molecular scaffolds (imidazole, oxazapine, diazapine, thiazole) rather than making incremental variants of existing antibiotics. This structural segmentation creates fundamentally different mechanisms of action that bypass existing resistance mechanisms while maintaining antibacterial activity.
Solution Approach 2:
The patent inverts the conventional approach by instead of modifying existing antibiotic structures, it uses privileged substructure-based diversity-oriented synthesis to create entirely new chemical frameworks. This inversion leads to novel compounds with unique biological activities that do not trigger existing resistance patterns.
2Reliability
If new antimicrobial agents are identified, then activity against resistant bacteria is improved, but therapeutic options remain limited
Solution Approach 1:
The patent applies universality by designing a platform of privileged substructures (imidazole, oxazapine, diazapine, thiazole) that can serve multiple therapeutic functions. These core scaffolds can be systematically modified to create libraries of compounds targeting different bacterial strains and resistance mechanisms, expanding therapeutic options while maintaining a unified structural foundation.
Solution Approach 2:
The patent uses parameter changes by systematically varying substituents on the core privileged substructures (different R groups, ring sizes, heteroatoms) to optimize activity against specific resistant bacterial strains. This allows tuning of pharmacological properties while maintaining the core active scaffold, thereby expanding therapeutic versatility.
3Reliability
If compounds with skeletal and stereochemical complexity are synthesized, then drug-like properties are improved, but synthesis efficiency decreases
Solution Approach 1:
The patent applies preliminary action by pre-establishing the privileged substructure frameworks (imidazole, oxazapine, diazapine, thiazole) with core stereochemical features already in place. This preliminary structuring allows subsequent rapid installation of diverse substituents through standardized reactions, maintaining synthesis efficiency while achieving complex drug-like molecules.
Solution Approach 2:
The patent uses parameter changes to systematically vary molecular complexity parameters (substituent types, ring configurations, stereochemistry) around the fixed privileged cores. This controlled parameter variation enables optimization of drug-like properties while maintaining efficient synthesis routes based on the pre-established core structures.
Data Source
AI summary
Novel heterocyclic fused systems are disclosed herein which possess numerous biological activities, including but not limited to antibacterial activity, and usefulness to the treatment of many disease states, such as pathogenic infections. In particular, new imidazoles are disclosed along with related processes of preparation and methods of use as antibacterial agents. The disclosed compounds were found to be active against several Gram-positive bacteria, including Enterococcus faecalis and Bacillus subtilis, and were also found to be active against several species of multi-drug resistant Staphylococcus, such as S. aureus, S. saprophyticus, S. haemolyticus, and S. epidermidis.